Standout Papers

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic<i>EG... 2008 2026 2014 2020 654
  1. First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations (2008)
    Lecia V. Sequist, Renato Martins et al. Journal of Clinical Oncology
  2. A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer (2008)
    J. Randolph Hecht, Edith P. Mitchell et al. Journal of Clinical Oncology
  3. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study (2018)
    Scott Gettinger, Leora Horn et al. Journal of Clinical Oncology
  4. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial (2017)
    Alice T. Shaw, Tae Min Kim et al. The Lancet Oncology
  5. Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab (2019)
    Suzanne L. Topalian, F. Stephen Hodi et al. JAMA Oncology
  6. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer (2016)
    Martin Reck, Alexander Luft et al. Journal of Clinical Oncology
  7. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study (2019)
    Funda Meric‐Bernstam, Herbert I. Hurwitz et al. The Lancet Oncology
  8. Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer (2013)
    David R. Spigel, Thomas J. Ervin et al. Journal of Clinical Oncology
  9. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study (2018)
    John D. Hainsworth, Funda Meric‐Bernstam et al. Journal of Clinical Oncology
  10. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study (2018)
    Fabrice Barlési, Johan Vansteenkiste et al. The Lancet Oncology
  11. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC (2019)
    Jhanelle E. Gray, Augusto Villegas et al. Journal of Thoracic Oncology
  12. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study (2021)
    Milind Javle, Mitesh J. Borad et al. The Lancet Oncology
  13. Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non–Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update (2017)
    Mark G. Kris, Laurie E. Gaspar et al. Journal of Clinical Oncology

Immediate Impact

7 by Nobel laureates 5 from Science/Nature 114 standout
Sub-graph 1 of 18

Citing Papers

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
Colorectal cancer
2024 Standout
19 intermediate papers

Works of David R. Spigel being referenced

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
2019 Standout
Genome-wide cell-free DNA (cfDNA) methylation signatures and effect on tissue of origin (TOO) performance.
2019
and 20 more

Author Peers

Author Last Decade Papers Cites
David R. Spigel 14076 9703 4947 603 19.4k
Mark A. Socinski 15354 14798 4880 516 22.4k
Fabrice Barlési 15052 13130 4919 566 21.4k
Patrick Schöffski 9407 9276 4736 500 18.9k
D. Ross Camidge 14715 16480 8384 533 23.6k
Martin Reck 17003 13355 4386 397 22.2k
Keunchil Park 17565 16632 6064 564 26.7k
Jaafar Bennouna 14021 7640 3481 336 17.8k
Jacek Jassem 11155 7771 4695 510 19.3k
Benjamin Besse 11848 10121 5484 697 18.1k
Emilio Bajetta 10203 5759 3860 323 16.3k

All Works

Loading papers...

Rankless by CCL
2026